We are live on ! Find out more
VBIO

Valion Bio
VBIO

3 hedge funds and large institutions have $187K invested in Valion Bio in 2025 Q2 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

345,431% more capital invested

Capital invested by funds: $54 → $187K (+$187K)

200% more funds holding

Funds holding: 1 → 3 (+2)

7.25% more ownership

Funds ownership: 0% → 7.25% (+7.2%)

Holders
3
Holders Change
+2
Holders Change %
+200%
% of All Funds
0.04%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
MG
Marex Group
+$169K
2
UBS Group
UBS Group
Switzerland
+$24.3K

Top Sellers

No sellers this quarter

VBIO Hedge Fund Activity: Q2 2025 in Review

3 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in Valion Bio (VBIO) for Q2 2025, worth a combined $187K — up 345,431% from $54 a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new VBIO positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Marex Group, opening a new position worth an estimated $169K.

  • 3 institutional investors held Valion Bio (VBIO) as of Q2 2025, up from 1 in Q1 2025.
  • Funds reported $187K of Valion Bio stock for Q2 2025, up 345,431% quarter-over-quarter.
  • 2 funds opened new Valion Bio positions in Q2 2025 and 0 closed out, a net change of +2 holders.
  • The largest Valion Bio buyer in Q2 2025 was Marex Group, an estimated $169K added.

Based on aggregated 13F filings for Q2 2025.